IL309054A - METHOD FOR MANUFACTURE OF DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE - Google Patents
METHOD FOR MANUFACTURE OF DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVEInfo
- Publication number
- IL309054A IL309054A IL309054A IL30905423A IL309054A IL 309054 A IL309054 A IL 309054A IL 309054 A IL309054 A IL 309054A IL 30905423 A IL30905423 A IL 30905423A IL 309054 A IL309054 A IL 309054A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- compound
- toluenesulfonate
- solvent
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/001—General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
- B01J2531/002—Materials
- B01J2531/004—Ligands
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/84—Metals of the iron group
- B01J2531/842—Iron
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021096200 | 2021-06-08 | ||
| PCT/JP2022/023068 WO2022260062A1 (ja) | 2021-06-08 | 2022-06-08 | ジヒドロピリダジン-3,5-ジオン誘導体の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309054A true IL309054A (en) | 2024-02-01 |
Family
ID=84426032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309054A IL309054A (en) | 2021-06-08 | 2022-06-08 | METHOD FOR MANUFACTURE OF DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115585A1 (https=) |
| EP (1) | EP4353718A4 (https=) |
| JP (1) | JP7665747B2 (https=) |
| KR (1) | KR20240019168A (https=) |
| CN (1) | CN117460727A (https=) |
| AR (1) | AR126060A1 (https=) |
| AU (1) | AU2022291310A1 (https=) |
| BR (1) | BR112023023841A2 (https=) |
| CA (1) | CA3221272A1 (https=) |
| IL (1) | IL309054A (https=) |
| MX (1) | MX2023013898A (https=) |
| TW (1) | TW202313590A (https=) |
| WO (1) | WO2022260062A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2525659B1 (en) * | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| CN102869656B (zh) | 2010-04-28 | 2014-03-12 | 安斯泰来制药株式会社 | 四氢苯并噻吩化合物 |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| KR101941048B1 (ko) | 2011-10-27 | 2019-01-22 | 아스텔라스세이야쿠 가부시키가이샤 | 아미노 알킬 치환 n-티에닐벤즈아미드 유도체 |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| PT2975030T (pt) * | 2013-03-13 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Derivado de di-hidropiridazina-3,5-diona |
| DE102013111551B3 (de) | 2013-10-21 | 2015-01-22 | Wago Verwaltungsgesellschaft Mbh | Tragschienengehäuse |
| MX383069B (es) | 2014-09-12 | 2025-03-13 | Chugai Pharmaceutical Co Ltd | Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio. |
| US10934280B2 (en) | 2016-08-15 | 2021-03-02 | Eli Lilly And Company | Condensed thiophene derivatives useful as NaPi-IIb inhibitors |
| CN111801335A (zh) | 2018-01-17 | 2020-10-20 | 株式会社神钢环境舒立净 | 亚硼酸酯化合物的合成方法、亚硼酸酯化合物的钠盐及其合成方法 |
-
2022
- 2022-06-02 AR ARP220101463A patent/AR126060A1/es unknown
- 2022-06-08 AU AU2022291310A patent/AU2022291310A1/en active Pending
- 2022-06-08 WO PCT/JP2022/023068 patent/WO2022260062A1/ja not_active Ceased
- 2022-06-08 TW TW111121209A patent/TW202313590A/zh unknown
- 2022-06-08 CN CN202280041402.9A patent/CN117460727A/zh active Pending
- 2022-06-08 EP EP22820241.2A patent/EP4353718A4/en active Pending
- 2022-06-08 CA CA3221272A patent/CA3221272A1/en active Pending
- 2022-06-08 JP JP2023527885A patent/JP7665747B2/ja active Active
- 2022-06-08 MX MX2023013898A patent/MX2023013898A/es unknown
- 2022-06-08 KR KR1020237045198A patent/KR20240019168A/ko active Pending
- 2022-06-08 US US18/567,432 patent/US20250115585A1/en active Pending
- 2022-06-08 IL IL309054A patent/IL309054A/en unknown
- 2022-06-08 BR BR112023023841A patent/BR112023023841A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP4353718A1 (en) | 2024-04-17 |
| BR112023023841A2 (pt) | 2024-01-30 |
| JP7665747B2 (ja) | 2025-04-21 |
| EP4353718A4 (en) | 2025-11-05 |
| US20250115585A1 (en) | 2025-04-10 |
| CN117460727A (zh) | 2024-01-26 |
| MX2023013898A (es) | 2023-12-11 |
| WO2022260062A1 (ja) | 2022-12-15 |
| CA3221272A1 (en) | 2022-12-15 |
| AU2022291310A1 (en) | 2024-01-18 |
| JPWO2022260062A1 (https=) | 2022-12-15 |
| KR20240019168A (ko) | 2024-02-14 |
| TW202313590A (zh) | 2023-04-01 |
| AR126060A1 (es) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL305033A (en) | Cyclic aromatic pyrimidine compounds | |
| IL263812B2 (en) | A process for the preparation of a polycyclic derivative of a modified pyridone and a hymane crystal | |
| IL298670A (en) | Inhibitors of kras g12c protein and uses thereof | |
| IL294136A (en) | A pyridazinyl-thiazolecarboxamide compound | |
| IL297212A (en) | crystalline ret inhibitor | |
| IL268031A (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| IL272667B (en) | Imidazo-pyridine compounds as pad inhibitors | |
| IL300051A (en) | The composition containing an arylamide derivative | |
| IL301236A (en) | Crystal forms of the KRAS inhibitor G12C | |
| IL303519A (en) | Cystic fibrosis treatment methods | |
| IL284690B (en) | Process for preparing btk inhibitors | |
| IL268683B (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| IL225808A (en) | Sesquihydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate, process for its preparation and pharmaceutical compositions comprising it for treating diabetes and obesity | |
| IL273606A (en) | Derived ring fused as an A2A receptor inhibitor | |
| IL281391B1 (en) | Imidazopyridinone compound | |
| WO2025021188A1 (zh) | 二氨基环戊基取代的杂芳基衍生物及其用途和制备方法 | |
| JP2025041735A (ja) | ピラジン置換ニコチンアミドの固体形態ならびにその調製および使用 | |
| IL319883A (en) | Processes and intermediates for the preparation of cyclase-based geonalite fans | |
| IL309054A (en) | METHOD FOR MANUFACTURE OF DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | |
| JP2026053339A (ja) | Ahrアゴニスト | |
| IL272556B2 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H[3,1]dioxo[5,4-F]indol-7-yl)pyrrole-5,2-dione | |
| CN109996800B (zh) | 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体 | |
| IL275153B2 (en) | Fumarate salts of (R)-3-(1-(2, 3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods for their preparation and use | |
| IL302652A (en) | Process for preparation of 2-hydroxy-6-((2-(1-isopropyl- 1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| HK40103591A (zh) | 二氢哒嗪-3,5-二酮衍生物的制造方法 |